Kevin美股成长价投2019-12-31 06:31
$Orgenesis(ORGS)$ $BioLife Solutions(BLFS)$ 近几年美国细胞治疗和再生医学领域发展迅速,投入资本年增长速度超过20%,Orgs为其它公司提供研发服务。算是这波细胞治疗和再生医学淘金热潮里卖铲子的商家。所以近几年公司录的非常稳定而高速的营收增长。股价从高位大幅调整下来,已经开始修复,目...查看全文
牛唐2019-10-11 22:12
$BioLife Solutions(BLFS)$ 全部收购了SAVSU,受益于细胞疗法的火热,2019年收入指引是增长39%,毛利率是七成左右,目前股价回调的厉害,可以关注查看全文
$BioLife Solutions(BLFS)$ 内部交易: 2021-03-22,Exec VP & Chief Scientific Off,Mathew Aby J. ,卖出,10000普通股, $37.80
$BioLife Solutions(BLFS)$ 内部交易: 2021-03-24,Exec VP & Chief Scientific Off,Mathew Aby J. ,卖出,10000普通股, $40.18
$BioLife Solutions(BLFS)$ 内部交易: 2021-03-24,Exec VP & Chief Scientific Off,Mathew Aby J. ,期权,10000普通股, $1.64
$BioLife Solutions(BLFS)$ 内部交易: 2021-03-22,Exec VP & Chief Scientific Off,Mathew Aby J. ,期权,10000普通股, $1.64
$BioLife Solutions(BLFS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-21-007080 Size: 8 KB 网页链接
$BioLife Solutions(BLFS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-21-007081 Size: 14 KB 网页链接
$BioLife Solutions(BLFS)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001437749-21-006752 Act: 34 Size: 569 KB 网页链接
$BioLife Solutions(BLFS)$ 内部交易: 2021-03-15,Director,Hinson Andrew G ,卖出,2500普通股, $37.32
$BioLife Solutions(BLFS)$ 内部交易: 2021-03-15,Chief Marketing Officer,Berard Todd ,卖出,6160普通股, $36.91
$BioLife Solutions(BLFS)$ 内部交易: 2021-03-16,Chief Marketing Officer,Berard Todd ,卖出,6160普通股, $36.72